SAN DIEGO, CA – January 25, 2011 – AndroScience Corp. (ASC), based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). Through a joint research effort with the Neurogenetics Branch of the NINDS, ASC will use the funding to pursue development of an oral drug treatment for spinal and bulbar muscular atrophy (SBMA) or Kennedy’s Disease, a rare hereditary neurodegenerative disease, which currently has no approved drug available to patients. Key pathological features of SBMA include progressive motor neuropathy and androgen insensitivity syndrome caused by a distinctive mutation within the androgen receptor (AR) gene. ASC has developed a unique platform of therapeutic small molecule drugs, which selectively and potently enhance degradation of the AR protein, termed AR degradation enhancers (ARD enhancers).
San Diego, CA
May 20, 2010, AndroScience Corporation (ASC) announced today the forming of a
strategic partnership with Orient Europharma Co. Ltd. (OEP) of Taiwan. The
collaborative agreement centers on the clinical development and
commercialization of ASC’s lead therapeutic candidate, ASC- J9
® as a
topical anti-acne product. Under
terms of the agreement OEP is responsible for clinical study
expenses related to an ASC-J9
® phase IIb multi center trial in
acne vulgaris. Scheduled to commence in September 2010, the 180 patients,
double-blinded, placebo controlled efficacy study will be jointly conducted at
clinical sites in Taiwan and
the USA.
San Diego, CA. - March 6, 2009, AndroScience Corporation (ASC
TM), a developmental stage pharmaceutical company announced results of a Phase 2a dose-ranging study of their lead clinical compound for the treatment of acne. The randomized, double-blinded, vehicle-controlled study completed in late 2008 enrolled 186 patients with acne and consisted of twice daily topical applications of ASC-J9
®cream for 12 weeks to evaluate safety and ascertain preliminary efficacy.
AndroScience Corporation (ASC), a San Diego-based biotech company, is developing ASC-J9
®as a topical agent for the treatment of acne.
AndroScience has completed a $6.4 million private-equity financing. The
company’s latest round of financing was led by President Life Sciences
Co., Ltd., joined by Eminent Venture Capital and other private
investors.
AndroScience Corporation (ASC), a San Diego based biotech company,
is developing ASC-J9 as a topical agent for the treatment of acne.